These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8950526)

  • 1. Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli.
    Pohlman JK; Knapp CC; Ludwig MD; Washington JA
    Diagn Microbiol Infect Dis; 1996 Sep; 26(1):29-33. PubMed ID: 8950526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.
    Hyatt JM; Nix DE; Stratton CW; Schentag JJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1711-6. PubMed ID: 7486906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe.
    Livermore DM; Yuan M
    J Antimicrob Chemother; 1996 Sep; 38(3):409-24. PubMed ID: 8889716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa.
    Pendland SL; Messick CR; Jung R
    Diagn Microbiol Infect Dis; 2002 Jan; 42(1):75-8. PubMed ID: 11821176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
    Burgess DS; Hastings RW
    Diagn Microbiol Infect Dis; 2000 Sep; 38(1):37-41. PubMed ID: 11025182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates.
    Jung R; Husain M; Choi MK; Fish DN
    Antimicrob Agents Chemother; 2004 Mar; 48(3):1055-7. PubMed ID: 14982809
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bactericidal activity of combinations of ticarcillin-clavulanic acid or other beta-lactams (amoxicillin, piperacillin-tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium].
    Leclercq R; Duval J
    Pathol Biol (Paris); 1995 Apr; 43(4):245-52. PubMed ID: 7567109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
    Fass RJ; Prior RB
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clavulanic acid in combination with ticarcillin: an in-vitro comparison with other beta-lactams.
    Clarke AM; Zemcov SJ
    J Antimicrob Chemother; 1984 Feb; 13(2):121-8. PubMed ID: 6323375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results.
    Jones RN; Sutton LD; Cantrell HF; Lankford RB
    Diagn Microbiol Infect Dis; 1994 Nov; 20(3):143-9. PubMed ID: 7874881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Pagani L; Migliavacca R; Luzzaro F; Giacobone E; Perilli M; Micheletti P; Amicosante G
    Chemotherapy; 1998; 44(6):377-84. PubMed ID: 9755296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer center.
    Rolston KV; Elting L; Waguespack S; Ho DH; LeBlanc B; Bodey GP
    Chemotherapy; 1996; 42(5):348-53. PubMed ID: 8874974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital.
    Platsouka E; Zissis NP; Constantoulaki S; Paniara O
    J Chemother; 1997 Oct; 9(5):336-40. PubMed ID: 9373788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of 500 gram negative isolates to determine the number of major susceptibility interpretation discrepancies between the Vitek and MicroScan Walkaway for 9 antimicrobial agents.
    Rittenhouse SF; Miller LA; Utrup LJ; Poupard JA
    Diagn Microbiol Infect Dis; 1996 Sep; 26(1):1-6. PubMed ID: 8950521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of piperacillin, ticarcillin, mezlocillin, ticarcillin-clavulanic acid, aztreonam, ceftazidime, azlocillin, cefoperazone, and thienamycin against Pseudomonas aeruginosa.
    Greenberg RN; Bollinger MR; Alivisatos MR
    Clin Ther; 1986; 8(6):655-7. PubMed ID: 3098426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
    Akova M; Yang Y; Livermore DM
    J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.
    Berrazeg M; Jeannot K; Ntsogo Enguéné VY; Broutin I; Loeffert S; Fournier D; Plésiat P
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6248-55. PubMed ID: 26248364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase.
    Knapp CC; Sierra-Madero J; Washington JA
    Diagn Microbiol Infect Dis; 1989; 12(6):511-5. PubMed ID: 2560423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.